IL6 and rheumatoid arthritis: Inhibition of this regulatory function has shown significant potential in reducing autoimmune inflammation by downregulating expression of key proinflammatory cytokines, including interleukin 6 (IL-6) and interferon-γ (IFNγ), making BET inhibition potentially therapeutic for RA [12].